Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Express Scripts
McKinsey
Cerilliant
Mallinckrodt
Fish and Richardson
Boehringer Ingelheim
Harvard Business School
Moodys

Generated: October 20, 2017

DrugPatentWatch Database Preview

Jazz Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for JAZZ PHARMS, and when can generic versions of JAZZ PHARMS drugs launch?

JAZZ PHARMS has five approved drugs.

There are twenty-six US patents protecting JAZZ PHARMS drugs.

There are ninety-eight patent family members on JAZZ PHARMS drugs in thirty countries and thirty-one supplementary protection certificates in seven countries.

Summary for Applicant: Jazz Pharms

International Patents:98
US Patents:26
Tradenames:5
Ingredients:5
NDAs:5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jazz Pharms
XYREM
sodium oxybate
SOLUTION;ORAL021196-001Jul 17, 2002AARXYesYes► Subscribe► Subscribe ► Subscribe
Jazz Pharms Iii
FAZACLO ODT
clozapine
TABLET, ORALLY DISINTEGRATING;ORAL021590-006Jul 9, 2010ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-004Dec 28, 2004RXYesYes► Subscribe► Subscribe ► Subscribe
Jazz Pharms Iii
FAZACLO ODT
clozapine
TABLET, ORALLY DISINTEGRATING;ORAL021590-005Jul 9, 2010ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-002Dec 28, 2004RXYesYes► Subscribe► Subscribe ► Subscribe
Jazz Pharms
LUVOX CR
fluvoxamine maleate
CAPSULE, EXTENDED RELEASE;ORAL022033-001Feb 28, 2008DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Jazz Pharms
XYREM
sodium oxybate
SOLUTION;ORAL021196-001Jul 17, 2002AARXYesYes► Subscribe► Subscribe ► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-004Dec 28, 2004RXYesYes► Subscribe► Subscribe ► Subscribe
Jazz Pharms
XYREM
sodium oxybate
SOLUTION;ORAL021196-001Jul 17, 2002AARXYesYes► Subscribe► SubscribeY ► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-003Dec 28, 2004DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Jazz Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-001Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-004Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-002Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-002Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-004Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms Iii
FAZACLO ODT
clozapine
TABLET, ORALLY DISINTEGRATING;ORAL021590-004May 30, 2007► Subscribe► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-002Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-003Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-003Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms Intl
PRIALT
ziconotide acetate
INJECTABLE;INTRATHECAL021060-001Dec 28, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for JAZZ PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
sodium oxybate
Oral Solution500 mg/mL
XYREM
7/8/2010
fluvoxamine maleate
Extended-release Capsules100 mg
LUVOX CR
4/20/2009
fluvoxamine maleate
Extended-release150 mg
LUVOX CR
4/13/2009

Non-Orange Book Patents for Jazz Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,268,774Method for reducing pain► Subscribe
6,087,091 Method of selecting a compound for producing analgesia► Subscribe
5,587,454 Omega conopeptide compositions► Subscribe
8,952,029Method of administration of gamma hydroxybutyrate with monocarboxylate transporters► Subscribe
8,461,203Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy► Subscribe
7,268,109Method for reducing pain► Subscribe
7,977,307Method for reducing pain with ziconotide and morphine► Subscribe
7,956,030Method for reducing pain with ziconotide and baclofen► Subscribe
7,524,812Pharmaceutical formulation comprising ziconotide► Subscribe
8,513,198Pharmaceutical formulation for reducing pain► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Jazz Pharms Drugs

Country Document Number Estimated Expiration
Canada2284663► Subscribe
World Intellectual Property Organization (WIPO)0038672► Subscribe
Spain2193777► Subscribe
Israel240874► Subscribe
Australia779354► Subscribe
China1264299► Subscribe
Hungary0003691► Subscribe
South Africa200110401► Subscribe
Hong Kong1215539► Subscribe
World Intellectual Property Organization (WIPO)9313128► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Jazz Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00014Denmark► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
C/GB07/011United Kingdom► SubscribePRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
C0108Belgium► SubscribePRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
C/GB00/021United Kingdom► SubscribePRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
C0005Belgium► SubscribePRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
C/GB98/025United Kingdom► SubscribePRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115
15/009Ireland► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
14/058Ireland► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Chubb
UBS
Chinese Patent Office
US Army
Merck
Baxter
Dow
Moodys
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot